News / Press Release

The Missing Step Between Phase I and Phase II

January 28, 2019
Too often, new drugs fail during development due to poor study design and inadequate knowledge about the performance of a new drug. A large part of these mistakes take place between Phase I and Phase II. That’s why TD2 created the Dynamic Trial, an adaptive approach that adds exploratory cohorts for faster insights earlier in the development process.

What’s the Dynamic Trial?

The DYNAMIC Trial features an add-as-you-go model, where expansion cohorts evolve as new data emerges. It appends exploratory cohorts to the Phase I trial to test various scenarios and clarify emerging questions about the drug’s actual performance. Small patient cohorts can be explored to define the best go-forward strategy.

What’s the Purpose?

The information gained in a Dynamic Trial study negates the need for exploratory Phase II trials, saving time and money. As a result, researchers can achieve in one trial what traditional models achieve in as many as four separate trials.

Is the Dynamic Trial for Me?

If you lack confidence in your drug’s registration pathway and need more verification points before advancing to a definitive or pivotal Phase II—or you’re considering several trial designs at once—you might want to consider this unique, adaptive trial design before moving straight to Phase II.

Is It FDA-Supported?

As a form of adaptive design, the Dynamic Trial model is not just supported by the FDA—it’s recommended. Just a few months ago, for example, the agency released a guidance document that aims to modernize trials with this adaptive approach which TD2 has been performing for a decade.

About Translational Drug Development (TD2)

TD2 is an oncology development organization that provides innovative services for oncology-focused companies. Using a dedicated team of professionals with broad experience and understanding in drug development, TD2 is uniquely positioned to support improved and accelerated development of medicines for life-threatening oncology diseases. TD2 applies rigorous and high-throughput translational preclinical development, combined with regulatory affairs expertise, to customize clinical trial design and execution. TD2’s suite of capabilities encourages the timely selection of patient populations who are most likely to benefit from a new agent, and the rapid identification of clinically significant endpoints. TD2 is committed to reducing the risks and uncertainty inherent in the drug development process and to the acceleration of patient access to promising treatments. For more information, visit www.TD2inc.com.

About TD2

TD2 is an oncology development organization that provides innovative services for oncology-focused companies. Using a dedicated team of professionals with broad experience and understanding in drug development, TD2 is uniquely positioned to support improved and accelerated development of medicines for life-threatening oncology diseases. TD2 applies rigorous and high-throughput translational preclinical development, combined with regulatory affairs expertise, to customize clinical trial design and execution. TD2’s suite of capabilities encourages the timely selection of patient populations who are most likely to benefit from a new agent, and the rapid identification of clinically significant endpoints. TD2 is committed to reducing the risks and uncertainty inherent in the drug development process and to the acceleration of patient access to promising treatments. For more information, visit www.TD2inc.com.

Contact
Tara Franks
602-358-8322
Get free tips, tools and resources by subscribing to the TD2 Newsletter: